Unlock the Potential of Rivaroxaban Synthesis
Discover the essential properties and applications of this vital pharmaceutical intermediate.
Get a Quote & SampleProduct Core Value
(S)-4-(4-(5-(Aminomethyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one
This compound, identified by CAS number 446292-10-0, is a pivotal intermediate in the production of Rivaroxaban, a widely used anticoagulant. Its high purity and specific chemical structure are critical for the efficacy and safety of the final drug product.
- Explore the crucial role of pharmaceutical intermediates for anticoagulants in drug development.
- Learn about the chemical properties of rivaroxaban impurity and its impact on synthesis.
- Find reliable suppliers to buy 446292-10-0 CAS for your manufacturing needs.
- Understand the diverse uses of (S)-4-(4-(5-(aminomethyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one in advanced pharmaceutical synthesis.
Key Advantages
Ensured Purity for Critical Applications
With an assay of ≥98.0%, this intermediate guarantees the quality required for pharmaceutical-grade chemical intermediates and successful drug development.
Streamlined Rivaroxaban Synthesis
As a key Rivaroxaban intermediate, it significantly simplifies and optimizes the rivaroxaban synthesis process, reducing complexity and potential side reactions.
Reliable Sourcing
Secure your supply chain with a dependable source for this essential compound, ensuring uninterrupted production of vital medications.
Key Applications
Rivaroxaban Synthesis
The primary application is as a key building block in the multi-step synthesis of Rivaroxaban, contributing to the creation of essential anticoagulant therapies.
Pharmaceutical Impurity Standards
Used as a reference standard for quality control, helping to identify and quantify related impurities in Rivaroxaban production.
Chemical Synthesis Research
Valuable in chemical synthesis research, particularly for developing novel routes or optimizing existing processes for complex pharmaceutical molecules.
Drug Development Support
Essential for drug development stages, including Abbreviated New Drug Application (ANDA) and Drug Master File (DMF) submissions, ensuring regulatory compliance.